Evaluating MB-106 in B-NH Lymphoma and CL Leukemia: Mazyar Shadman, MD
The associate professor from Fred Hutchinson Cancer Research Center discussed the methods utilized in an ongoing phase 1/2 trial evaluating MB-106.
This content originally appeared on our sister site, OncLive.
An ongoing phase 1/2 trial (NCT03277729) is evaluating MB-106, an investigational CD20-directed CAR T-cell therapy, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL).
OncLive spoke with Mazyar Shadman, MD, MPH, physician, Seattle Cancer Care Alliance, associate professor, Division of Medical Oncology, University of Washington School of Medicine, associate professor, Clinical Research Division, Fred Hutchinson Cancer Research Center, to learn more about the trial.
The study enrolled patients with CD20-positive B-NHL. Shadman discussed how each histology had specific eligibility criteria that varied for high-grade vs low-grade lymphomas vs CLL. Overall, if patients expressed the CD20 target, they were considered eligible for enrollment.
Moreover, patients underwent biopsies was required to biopsy patients both before and after infusion. Otherwise, the study schema was similar to that observed in the clinical trials evaluating CD19-directed CAR T-cell therapies, Shadman continued. Additionally, MB-106 is given as an outpatient therapy. Excluding the first patient treated in each dose cohort, patients received MB-106 in the outpatient setting, Shadman concluded.
